Logo image
Back
Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor
Journal article   Open access   Peer reviewed

Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor

Raymond L. Benza, Mark Doyle, David Lasorda, Kishan S. Parikh, Priscilla Correa-Jaque, Nima Badie, Greg Ginn, Sophia Airhart, Veronica Franco, Manreet K. Kanwar, …
Chest, v 156(6), pp 1176-1186
01 Dec 2019
DOI: https://doi.org/10.1016/j.chest.2019.06.010
PMID: 31265832
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904858View
Published, Version of Record (VoR)Open Access (License Unspecified),  Open

Abstract

CardioMEMS pulmonary hypertension ride-sided heart failure Hemodynamics
Pulmonary arterial hypertension (PAH) is a chronic disease that ultimately progresses to right-sided heart failure (HF) and death. Close monitoring of pulmonary artery pressure (PAP) and right ventricular (RV) function allows clinicians to appropriately guide therapy. However, the burden of commonly used methods to assess RV hemodynamics, such as right heart catheterization, precludes frequent monitoring. The CardioMEMS HF System (Abbott) is an ambulatory implantable hemodynamic monitor, previously only used in patients with New York Heart Association (NYHA) class III HF. In this study, we evaluate the feasibility and early safety of monitoring patients with PAH and right-sided HF using the CardioMEMS HF System. The CardioMEMS HF sensors were implanted in 26 patients with PAH with NYHA class III or IV right-sided HF (51.3 ± 18.3 years of age, 92% women, 81% NYHA class III). PAH therapy was tracked using a minimum of weekly reviews of CardioMEMS HF daily hemodynamic measurements. Safety, functional response, and hemodynamic response were tracked up to 4 years with in-clinic follow-ups. The CardioMEMS HF System was safely used to monitor PAH therapy, with no device-related serious adverse events observed and a single preimplant serious adverse event. Significant PAP reduction and cardiac output elevation were observed as early as 1 month postimplant using trends of CardioMEMS HF data, coupled with significant NYHA class and quality of life improvements within 1 year. The CardioMEMS HF System provided useful information to monitor PAH therapy, and demonstrated short- and long-term safety. Larger clinical trials are needed before its widespread use to guide therapy in patients with severe PAH with right-sided HF.

Metrics

10 Record Views
48 citations in Web of Science
49 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Critical Care Medicine
Respiratory System
Logo image